You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 28, 2012

PLC Life Sciences Multi-Jurisdictional Guide 2012 – Vietnam Chapter

Practical Law Company

With the tightening of budgets and increased scrutiny by the Ministry of Health, this article delves into the practicability of Vietnam’s regulatory framework governing the life sciences industry. Ranging from the quality of national healthcare, manufacturing authorization, marketing, and pricing of medicinal products, to the intellectual property surrounding each product and the scope of product liability law in this industry, this Q&A chapter provides a detailed overview of the effect of key legislation and the power of regulatory authorities. In particular, the chapter covers:

  • Pricing Structure: Costs and state funding of medicinal products and national healthcare
  • Manufacturing: Authorization, conditions, fees, and validity of licenses
  • Marketing: Fees, conditions, authorization, packaging requirements, foreign marketing authorizations, parallel imports, and restrictions such as marketing on the internet
  • Traditional Medicine: Manufacturing and marketing regulations
  • Patent Law: Conditions, patentable products, scope of protection, validity, revocation, infringement, and remedies available
  • Trademark Law: Conditions, scope of protection, duration of protection, revocation, infringement, remedies available, and relevant international conventions
  • Product Liability Law: Key legislation, the substantive test, procedures of bringing a claim, defenses and remedies available, limitation periods, and parties liable under the Consumer Protection Law
  • Proposals for Reform: The Draft Law on Advertisement, and further guidance through implementing circulars

This chapter was published by Practical Law Company, a leading provider of legal guidance, analysis, and market intelligence in up to 30 jurisdictions.

RELATED INSIGHTS​ 

April 23, 2019
The market for ­pharmaceuticals in Vietnam is developing rapidly, in step with the country’s growing and aging population, rising per capita income, and increasing awareness of foreign ­brand-name drugs, which many ­Vietnamese consumers consider to be more reliable than generics and local brands. ­Naturally, Vietnam has ­become an attractive ­investment ­destination for ­foreign pharmaceutical companies eager to ­target new ­customers.
April 5, 2019
Pyihtaungsu Hluttaw Law No. 9/2019—Myanmar’s new Consumer Protection Law—was enacted on March 15, 2019, repealing the previous law and providing a clearer legal framework for the protection of consumers in Myanmar. The date of implementation is March 15, 2019, with the exception of the product label requirement, which will enter into force one year after the date of enactment.  
March 21, 2019
Since the entry into effect of the 2016 Law on Pharmacy and the subsequent Decree 54/2017/ND-CP (Decree 54), pharmaceutical companies in Vietnam were eagerly awaiting a replacement for Circular No. 44/2014/TT-BYT on drug registration (Circular 44), which was based on the now-defunct Law on Pharmacy of 2005. Finally, on November 12, 2018, Circular No. 32/2018/TT-BYT (Circular 32) was issued. This circular will take effect on September 1, 2019, and will play an important role in the pharmaceutical regulatory landscape in Vietnam.
March 1, 2019
Vietnam’s Central Party Steering Committee recently issued a strong directive ordering strict policies emphasizing improved consumer protection. Specifically, Directive No. 30/CT/TW on Strengthening Party Leadership and State Management Responsibility in Consumer Protection (Directive 30) was issued on 22 January 2019.